Substance use disorders (SUDs) remain among the most challenging conditions in mental health care. Despite decades of research and clinical innovation, relapse rates remain stubbornly high, and many individuals struggling with addiction find themselves cycling through treatments that offer only temporary relief [1]. This reality has sparked renewed interest in a category of compounds that first captured psychiatric attention over seventy years ago: psychedelics.
The resurgence of psychedelic research represents more than scientific curiosity—it reflects an urgent need for novel therapeutic approaches. From psilocybin to ketamine to ayahuasca, these substances are being investigated not as recreational drugs, but as potential catalysts for profound psychological change. What emerges from the growing body of evidence is a nuanced picture: one of genuine therapeutic promise tempered by the need for careful implementation, particularly when working with vulnerable populations.
The Historical Arc of Psychedelic Medicine
The story of psychedelics in addiction medicine begins in the early 1950s. Following Albert Hofmann’s discovery of LSD in Switzerland in 1943, researchers began exploring therapeutic applications with remarkable enthusiasm. By 1961, over 1,000 articles on LSD had appeared in medical journals [2]. These early investigators weren’t operating on the fringes—they were working in university hospitals and research centers, publishing in mainstream psychiatric literature.
The treatment of alcohol use disorder was a primary focus from the outset. Humphry Osmond and Abram Hoffer began treating alcohol use disorder with LSD at the University Hospital in Saskatchewan in 1953, and the next seven years saw an almost exclusively Canadian research program that consistently found promising results [3]. The therapeutic rationale was both practical and philosophical: psychedelics might help patients achieve the kind of profound realization that AA members described as “hitting bottom”—but without the devastating consequences that often preceded such transformations.
Early clinical results were encouraging. In one study conducted in British Columbia, Canada, 61 patients with alcohol use disorder who had been unsuccessful with AA received LSD along with psychotherapy. At follow-up periods of 3–18 months, half were much improved [4]. The largest and longest-running US program, the Spring Grove research project, founded in 1963, continued to expand its scope until political pressures forced its closure in 1976 [3].
President Nixon’s Controlled Substances Act of 1970 effectively ended this first wave of research by classifying psychedelics as Schedule I substances with no accepted medical use. The decision was driven largely by cultural politics rather than scientific evidence, and it created a research hiatus that would last decades. The renaissance began quietly in the early 2000s, and since 2004, over 2,000 articles investigating psychedelics for SUD and other psychiatric conditions have been published in peer-reviewed journals [2].
What the Current Evidence Tells Us
The contemporary research landscape is substantial and growing. Systematic reviews have examined dozens of clinical trials conducted between 2013 and 2024, consistently finding that psychedelics like psilocybin and ayahuasca show promise in reducing alcohol and tobacco dependence, with psilocybin demonstrating notable effectiveness in decreasing cravings and promoting longer-term abstinence [5]. Studies have revealed significant improvements in substance use reduction, especially when psychedelic administration is combined with psychotherapy.
A recent meta-analysis examining psychedelics specifically for SUD found that among the substances studied, ibogaine showed the most prominent effects, with six studies involving 240 participants all demonstrating significant overall improvements, yielding the highest effect size [6]. Meanwhile, ketamine has been investigated in multiple randomized controlled trials for alcohol, cocaine, opioid, and nicotine use disorders. One systematic review found that ketamine reduced withdrawal symptoms and benzodiazepine requirements in alcohol use disorder, decreased craving and increased abstinence rates in cocaine use disorder, and improved abstinence while reducing cravings in opioid use disorder when combined with therapy [7]. The emerging consensus suggests efficacy, particularly when ketamine produces doses sufficient to induce mystical or profound psychological experiences. Ketamine’s effect on altering extracellular glutamate levels may therapeutically benefit corticolimbic system connectivity disruptions that keep patients stuck in SUDs [8].
Perhaps most striking is data from a large cohort study analyzing nearly 3.2 million electronic health records from patients with documented SUD diagnoses. This real-world evidence found that psychedelic use was associated with significantly reduced rates of overdose, relapse, mental health crises, and hospitalizations compared to no treatment—particularly when combined with outpatient care [9]. Complementing this, a cross-sectional study of 466 individuals with chronic pain found that 86.3% reported ceasing or decreasing use of one or more non-psychedelic substances following psychedelic use, with 21.2% indicating these changes persisted for more than 26 weeks [10]. While observational data must be interpreted cautiously, such findings at scale add meaningful context to controlled trial results.
It’s worth noting that the evidence base, while promising, is not without limitations. Meta-analyses examining serotonergic psychedelics and MDMA have found moderate to large effect sizes for PTSD, depression, and anxiety disorders, but results for alcohol use disorder specifically have been more variable [11]. The field is still young, and gaps persist due to historical barriers rooted in political and ethical challenges [5].
Understanding How Psychedelics May Help
Several converging lines of research are illuminating how psychedelics might facilitate recovery from addiction. At the neural level, these substances appear to disrupt maladaptive circuits and promote neuroplasticity—the brain’s capacity to reorganize and form new connections [12]. Both serotonergic psychedelics and ketamine recruit glutamatergic neurons to stimulate BDNF-TrkB signaling, which promotes the growth of new synaptic connections via the mTOR pathway [13]. This synaptic remodeling may be particularly relevant in the prefrontal cortex, a region critical for decision-making and impulse control.
A key focus of current research involves the default mode network (DMN)—a collection of brain regions active during self-referential thought and introspection. In addictive disorders, the DMN appears to become overly dominant, reinforcing rigid patterns of thinking and behavior. Psychedelics temporarily reduce DMN activity, leading to what researchers describe as enhanced “cognitive flexibility” and a temporary dissolution of ego boundaries [12]. This disruption may explain why participants often report experiencing fresh perspectives on their relationship with substances and themselves.
The psychological dimension cannot be separated from the neurobiological. Across studies, participants commonly report improved self-compassion and emotional regulation following psychedelic-assisted therapy. These experiences appear to help individuals confront past trauma, negative emotions, and self-critical thoughts—factors intimately connected with addictive patterns [5]. The effects are often linked to “mystical” or profoundly meaningful experiences during treatment sessions, which may catalyze lasting behavioral changes.
Emerging research has also begun exploring the gut-brain axis, with evidence suggesting that psychedelics may modulate gut microbial composition while gut bacteria influence how these compounds are metabolized [14]. Anti-inflammatory properties have also been documented, with psilocybin shown to reduce inflammatory gene expression in brain regions implicated in reward and relapse [15]. These findings hint at mechanisms of action that extend beyond receptor binding and neural circuits.
Harm Reduction and Safety Considerations
A harm reduction perspective on psychedelic-assisted therapy acknowledges both the potential benefits and the real risks these substances carry. Safety data are generally reassuring—psychedelic-related deaths remain very rare compared to other recreational drugs and frequently involve polydrug use [16]. However, “rare” is not “absent,” and the clinical context matters enormously.
Documented adverse effects include autonomic instability, cardiovascular and respiratory side effects, anxiety, agitation, dysphoria, confusion, and dissociative experiences [1]. While these are typically not life-threatening, ibogaine is a notable exception requiring cardiac monitoring—one 12-month follow-up study of ibogaine treatment for opioid dependence reported a patient death during treatment [17]. This underscores the importance of proper medical screening, supervised settings, and appropriate follow-up care. Challenging psychological experiences during sessions, while often associated with beneficial outcomes afterward, can trigger distress and require skilled therapeutic support.
The tension between access and safety remains unresolved in the current regulatory landscape. Five types of legal pathways now facilitate access to psychedelics in various jurisdictions: decriminalization, supported adult use, medical use frameworks, clinical trials, and formal religious exemptions [18]. Each carries trade-offs. Overly restrictive gatekeeping risks pushing individuals toward unregulated markets or denying promising treatments to those with unmet needs. Insufficient oversight risks harm to vulnerable populations, including those prone to psychosis or lacking adequate integration support.
Medical settings aim to strike the optimal balance: using the lowest effective dose of a quality-controlled product, in a highly controlled environment, with careful monitoring for adverse events [19]. This framework protects patients while allowing access to potentially transformative treatment. Expanded Access or “Right to Try” pathways represent another emerging option for patients unable to participate in trials and lacking other treatment options, though securing physician agreement and product access remains challenging [20].
Integration with Recovery Frameworks
One of the more nuanced questions in this field concerns how psychedelic-assisted therapy interfaces with established recovery approaches, particularly 12-Step programs. Qualitative research has explored this intersection, revealing both synergies and tensions. Participants who combined psychedelic experiences with 12-Step engagement described the substances as tools for accessing deeper self-understanding and confronting trauma in ways that conventional approaches had not facilitated [21].
“Ayahuasca shows me what I am from a different angle that allows my perspective to change,” reported one participant. Another described stalling out in emotional recovery despite trying yoga, sweat lodges, and therapy, ultimately turning to ayahuasca as medicine that might help where other approaches had not [21]. The socio-structural aspects of setting—participating in ceremonies within supportive communities—appeared to contribute meaningfully to perceived benefits.
Similar themes emerged from research with Indigenous communities in Canada, where ayahuasca-assisted retreats helped participants identify negative thought patterns in ways that differed from conventional therapies. “Every time that I come back out from a treatment center, I do good for a while and then that old mentality comes back…things have changed now. I feel a lot better…healthier. My mind is more clear,” one participant explained. Another described the transformation in vivid terms: “I got my spirit back…Like it is so beautiful outside, and where was all that all this time? You know, I was just living with a black cloud over me. And the black cloud’s been removed” [22]. Participants reported not just reduced substance use and cravings, but renewed connection to spirit, beauty in the world, and love and respect for others.
The risks within this integration are real and should not be minimized. Challenging experiences could trigger a return to unhealthy coping; psychedelic misuse is a meaningful concern; unmonitored use is particularly problematic for psychosis-prone individuals; and limited follow-up support may diminish long-term benefits [21]. Furthermore, psychedelic use sits in tension with 12-Step principles of abstinence, creating potential conflicts for individuals navigating both worlds. These complexities require honest acknowledgment rather than dismissal.
Looking Forward
The future of psychedelic-assisted therapy for SUD likely involves continued refinement of protocols, better understanding of who benefits most, and creative integration with existing treatment modalities. Researchers are exploring adjunctive approaches such as virtual reality, which might help prepare patients for psychedelic experiences, extend therapeutic effects, facilitate integration, and standardize the set and setting variables that influence outcomes [23].
Important gaps in the current research base need to be addressed. Studies have significantly underrepresented women—of 75 studies reviewed in one analysis, 46 had female representation below 45% and 9 included no women at all [24]. Given documented sex differences in addiction patterns and treatment responses, ensuring adequate representation is essential for generalizable findings.
The question of how to balance innovation with caution remains central. Psychedelic-assisted therapy offers something different from conventional pharmacotherapy: not a medication taken daily to manage symptoms, but a catalyst for transformative experiences within a therapeutic container. Early researchers noted that changes following treatment, while initially profound, could fade as patients returned to old environments and patterns [3]. This observation underscores the importance of integration support, community connection, and addressing the social determinants that contribute to addiction.
Conclusion
Psychedelic medicine for SUDs has traveled a remarkable arc—from mainstream psychiatric research in the 1950s, through decades of prohibition, to the current renaissance of rigorous clinical investigation. The evidence accumulated thus far suggests genuine therapeutic potential, particularly when these substances are administered within supportive therapeutic frameworks that address both preparation and integration.
A harm reduction perspective on this work holds multiple truths simultaneously: that conventional treatments leave many patients inadequately served; that psychedelics offer mechanisms of action distinct from existing pharmacotherapies; that real risks require careful screening, monitoring, and follow-up; and that access considerations must balance protection with the reality that gatekeeping itself carries costs. The goal is not psychedelic exceptionalism, but thoughtful integration of these tools where they can genuinely help.
For individuals struggling with addiction and the clinicians who serve them, the message is one of cautious optimism. The research is promising but evolving. The implementation matters as much as the molecule. And the work of recovery—whatever tools support it—ultimately involves the hard human work of building new patterns, new connections, and new ways of being in the world.
Fourteen Critical Things Individuals with Substance Use Disorder Histories Should Know About Psychedelic Medicine
The following guidelines emerge from the intersection of clinical research, traditional practice, and the author’s training in psychedelic-assisted therapy. They are offered as expert synthesis rather than established protocol, intended to support safer decision-making for individuals with SUD histories who are considering this work.
Phase I: Decision-Making
1. There are three pathways: medical, ceremonial, and recreational
Medical and ceremonial pathways are advised; recreational use is not recommended for individuals with SUD histories. Both medical and ceremonial paths require structured settings with reputable facilities and trained practitioners. Recreational use—including serving yourself medicine—carries an elevated risk. Microdosing is a form of self-administration that may be appropriate in some cases, but only with accountability to a group or individual. For the safest possible path, never serve yourself medicine.
2. Complete a thorough medical screening before beginning
Individuals with SUD histories often have co-occurring conditions that require evaluation, including cardiovascular issues, liver function concerns, and psychiatric comorbidities. Some psychedelic medicines (e.g., ibogaine) carry significant cardiac risks and require ECG screening. Others may be contraindicated in certain medical conditions. A comprehensive medical intake, lab work as indicated, and psychiatric assessment should precede any psychedelic medicine work.
3. Understand medication interactions and tapering requirements
Many individuals with SUD histories are on medications that interact with psychedelics—including MAT (buprenorphine, methadone, naltrexone), SSRIs, SNRIs, benzodiazepines, and antipsychotics. Some combinations can be dangerous (e.g., serotonin syndrome risk with MDMA and SSRIs), while others may blunt the psychedelic experience. Medication tapering, when indicated, should be done under medical supervision and completed well before the medicine session. Never abruptly discontinue prescribed medications without guidance.
Phase II: Preparation
4. The preparation on-ramp for a first psychedelic experience should be several months
Adequate preparation involves more than scheduling a session. Talk to people who have experience, watch documentaries, learn the history of these medicines, and explore your intentions. Feel solid about your decision—this reduces the chance of regret or ambivalence arising during the experience itself. Rushing into psychedelic work without proper preparation undermines outcomes and can increase psychological risk.
5. Give something up in the weeks leading up to the experience
For at least one to two weeks before medicine work, consider abstaining from caffeine, nicotine, sugar, or other habitual behaviors. This process gives the dopamine system a rest and builds the muscle of intentional restraint. Battling addictive patterns during preparation is far easier than wrestling with them during the medicine experience. In many traditions, this is known as a “dieta”—a period of cleansing and focus that prepares body and mind for the work ahead.
6. Expect that difficult experiences are possible—and often therapeutic
Challenging emotions, memories, and somatic sensations are common during psychedelic experiences and are not signs of something going wrong. Anxiety, fear, grief, and even temporary feelings of overwhelm can be part of the healing process. What matters is how these experiences are held and integrated. Preparation should include discussion of coping strategies and grounding techniques, and an understanding that “difficult” does not mean “bad.” The therapeutic value often emerges from moving through—not around—the hard material.
7. Have an emergency plan in place before the experience
Know who to call if something goes wrong—both during and in the days following the experience. This includes crisis hotlines, your therapist or integration specialist, a trusted friend, or medical support as needed. Agree in advance on a plan if you experience prolonged distress, activation of suicidal ideation, or psychiatric destabilization. Having a safety net in place allows you to surrender more fully to the experience, knowing support is available.
Phase III: The Experience & Disclosure
8. Don’t keep secrets, but not everybody needs to know your business
Someone who understands your history should know about these experiences—a therapist, partner, sponsor, or trusted friend. Secrecy breeds shame and undermines integration. However, you do not need to disclose to people who won’t understand your path, including those in traditional abstinence-based recovery communities where psychedelic use may be stigmatized or misunderstood. Choose your confidants wisely.
9. Respect the medicine teachings
The purpose of psychedelic medicine is to amplify lived experience—to reveal issues, illuminate strengths, and access the heart. If complex material surfaces, the medicine is trying to tell you something. This doesn’t mean you must interpret every vision or message as literal truth, but these experiences carry meaning and should be discussed with others. Don’t make major life decisions immediately after a session. If seeds are planted, water them—but do not rush to conclusions until integration work is complete. If you receive “downloads” or teachings, make some effort toward that work before returning to medicine. If you keep getting the same message because you haven’t put forth effort to change, it’s time to pause until something shifts.
Phase IV: Integration & Long-Term Sustainability
10. Create a buffer after medicine work to support integration
Avoid returning to high-stress life demands immediately. Give yourself several days of lighter schedules (if possible). During this time, discuss your experience with at least two people from your support network. Working with someone who specializes in integration—a therapist or trained integration coach—is strongly advised. The days and weeks following a session are when the real work of translating insight into lasting change takes place.
11. Use psychedelic medicine only a few times per year
For classic psychedelics (psilocybin, ayahuasca, LSD), a few times per year is a reasonable ceiling. If you find yourself seeking medicine more than once every quarter, consider this an early warning sign. Monthly use is a clear indicator that something has gone off course. Exception: some medicines like ketamine are administered on clinical schedules with multiple treatments over weeks—these protocols are different from the guidance here, which applies to classic psychedelics and ceremonial use.
12. The more you find presence/peace only with medicine, the harder it becomes to find it without
If you cannot recapture the serenity and presence from medicine work in your daily life, you risk developing a psychological dependence on the medicine state itself. When peace becomes accessible only during sessions, this is both a warning sign and an indication that a break is needed. The goal is to bring the lessons from medicine into ordinary life—not to require medicine to access them.
13. For people with SUD histories, dopaminergic activation can recruit old patterns
Substance-induced dopamine activation can bring back what might be called the “dark cloud” of addiction history. For many people, it doesn’t matter what the substance is—eventually, dopaminergic substances recruit familiar patterns of craving, compulsion, or dysregulation. Sticking with primarily serotonergic medicines (e.g., psilocybin, ayahuasca) and avoiding dopaminergic substances outside of structured ceremonial contexts is generally advised. If the dark cloud of addiction history keeps showing up during or after medicine work, this may be a sign to pause until further progress is made in recovery.
Phase V: Community & Ongoing Support
14. Spirituality lives in community
There are many spiritual communities and many recovery communities. You will likely encounter people in spiritual/psychedelic communities who don’t fully grasp addiction, and people in recovery communities who don’t understand or accept psychedelics. The task is to foster a community that includes people who understand both.
Communities holding both recovery wisdom and psychedelic understanding are being built in real time. To join this conversation and be a part of the movement toward better mental health, subscribe to our newsletter.
About the Author:
Dr. David Wiss, PhD, RDN, IFMCP, is a functional medicine practitioner specializing in treatment-resistant mental health conditions. His work integrates nutritional psychiatry, gut-brain medicine, and advanced functional testing to help patients address the root causes of depression, anxiety, and other psychiatric conditions.
References
[1] Correa de Costa YR, Pereira DB, Carvalho MTDM, et al. The role of psychedelics in the treatment of substance use disorders: An overview of systematic reviews. J Psychopharmacol. 2025.
[2] Dyck E. Flashback: psychiatric experimentation with LSD in historical perspective. Can J Psychiatry. 2005;50(7):381-388.
[3] Nichols DE. The history of psychedelics in psychiatry. Pharmacopsychiatry. 2020;53(3):77-84.
[4] MacLean JR, MacDonald DC, Byrne UP, Hubbard AM. The use of LSD-25 in the treatment of alcoholism and other psychiatric problems. Q J Stud Alcohol. 1961;22:34-45.
[5] Hogea LM, Nussbaum LA, Antal A, et al. The therapeutic potential of psychedelics in treating substance use disorders: A review of clinical trials. Front Psychiatry. 2025.
[6] Keighley C, Baksh S, Tsapekos D, et al. A systematic review and meta-analysis investigating the efficacy of various psychedelic drugs for the treatment of substance use disorder. J Psychopharmacol. 2025.
[7] Janssen-Aguilar R, Lopez-Canul M, Bhardwaj SK, et al. Role of ketamine in the treatment of substance use disorders: A systematic review. J Clin Med. 2025.
[8] Thomas AL, Bhattacharjee S, Oritz RJ, et al. Ketamine’s therapeutic role in substance use disorders: A narrative review. J Clin Med. 2025.
[9] Qeadan F, McCunn A, Engard B. Associations between psychedelic use and adverse outcomes in substance use disorders: A real-world EHR-based cohort study. J Psychiatr Res. 2025.
[10] Glynos NG, Goel N, Engel-Smith B, et al. Psychedelics and chronic pain: self-reported outcomes on changed substance use patterns and health following naturalistic psychedelic use. Front Pain Res. 2025.
[11] Højlund M, Andersen K, Østermark J, et al. Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis. Lancet Psychiatry. 2025.
[12] Li M, Yang S, Zhang X, et al. Exploring the therapeutic potential of psychedelics in treating substance use disorders. Neurosci Biobehav Rev. 2025.
[13] Palhas AP, Bhatt DG, Bhatt S. Changing your mind: neuroplastic mechanisms underlying the therapeutic effect of psychedelics in depression, PTSD, and addiction. Front Neurosci. 2025.
[14] Wang Z, Liu Y, Chen H. Psychedelics and the gut microbiome: Unraveling the interplay and therapeutic implications. Gut Microbes. 2025.
[15] Floris G, Castelli MP, Bhardwaj SK. Psilocybin reduces heroin seeking behavior and modulates inflammatory gene expression in the nucleus accumbens and prefrontal cortex of male rats. Neuropsychopharmacology. 2025.
[16] Kopra EI, Ferris J, Dargan PI, et al. Psychedelic-related deaths in England, Wales and Northern Ireland (1997-2022). J Psychopharmacol. 2025.
[17] Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46.
[18] Propes CR, Olson DE, Barnett BS. Gaps in US psychedelic research and how to close them. JAMA Psychiatry. 2025.
[19] Gomez-Escolar A, Garcia-Romeu A. Current perspectives on the clinical research and medicalization of psychedelic drugs for addiction treatments: Safety, efficacy, limitations and challenges. Curr Addict Rep. 2024.
[20] Lynch JL, Anderson BT, Smith-Apeldoorn SY. Addressing US demand for psychedelic medicines in the face of scientific uncertainty. NEJM. 2025.
[21] Mehtani N, Garcia-Romeu A, Johnson MW. Psychedelic augmentation of 12-Step engagement: A novel, accessible approach to enhance community-based recovery from substance use disorders. J Subst Abuse Treat. 2025.
[22] Argento E, Capler R, Thomas G, et al. Exploring ayahuasca-assisted therapy for addiction: A qualitative analysis of preliminary findings among an Indigenous community in Canada. Drug Alcohol Depend. 2019;199:33-41.
[23] Matthews P, Sahakian BJ, Robbins TW. Virtual reality and psychedelics: new perspectives and new possibilities in the treatment of alcohol use disorder. Alcohol Alcohol. 2025.
[24] Nigri A, Cippitelli M, Ferrara M. Psychedelics for substance use disorders: Are women being addressed? A scoping review. J Psychopharmacol. 2025.
